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Abstract
Introduction: To date, no studies have evaluated the incidence of rebound hypertension occurring with 
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been documented in the literature with clonidine, a structurally and pharmacologically similar 
medication. 
Objectives: To compare the incidence of rebound hypertension associated with cessation of 
dexmedetomidine infusion with other sedative medications.
Methods: This retrospective, matched cohort study evaluated the incidence of rebound hypertension in 
intensive care unit patients receiving continuous infusions of at least 72 hours in duration of 
dexmedetomidine, propofol, or midazolam.  
Results: The study population consisted of 216 patients, 54 treated with dexmedetomidine and 162 
treated with propofol or midazolam. Rebound hypertension occurred significantly more often in 
patients with a history of hypertension (71.1%) than in patients with no prior hypertension (28.9%; p < 
0.001).There was no difference in incidence of rebound hypertension in the dexmedetomidine or 
propofol and midazolam arms (16.7% vs 17.9%, p = 0.837). The titration timeframe for the 
dexmedetomidine infusion, defined as the time from peak infusion rate until discontinuation, was 
significantly shorter in patients with rebound hypertension (median duration, 4 hours) compared with 
patients who did not have rebound hypertension (median duration, 17 hours; p = 0.011).
Conclusion: There was no difference in the incidence of rebound hypertension observed with 
dexmedetomidine discontinuation compared with propofol or midazolam. Instead, history of 
hypertension and a shorter weaning duration appear to be associated with increased risk of rebound 
hypertension regardless of the sedative used.
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Background
Dexmedetomidine is a selective, centrally-acting alpha-2 adrenergic agonist that is structurally and 
pharmacologically similar to clonidine. However, dexmedetomidine is 8-fold more specific for the 2a 
subtype of the central alpha-2 adrenergic receptor than clonidine.1 Rebound hypertension can occur 
with abrupt discontinuation of clonidine, and tapering of the dose is recommended when therapy is 
discontinued. Rebound hypertension has been reported during the initiation of transdermal clonidine 
















This article is protected by copyright. All rights reserved
catecholamine release after the removal of the inhibitory effects of clonidine on the sympathetic 
nervous system. Because of structural and pharmacological similarities with clonidine, the prescribing 
information for dexmedetomidine includes a warning to avoid abrupt discontinuation in order to avoid 
rebound hypertension, though published accounts are limited to case reports. 
Rebound hypertension has not been reported in randomized controlled trials comparing 
dexmedetomidine to benzodiazepines or propofol.3,4,5,6 A 2014 study that compared the incidence of 
hypotension, hypertension, and bradycardia with dexmedetomidine infusion within 24 hours and 
beyond 24 hours found no significant differences in adverse events or evidence of withdrawal 
syndrome.7 Herein, we report the findings of our study designed to determine if rebound hypertension 
occurs more frequently after dexmedetomidine discontinuation than after discontinuation of other 
continuously infused sedative medications.
Methods
Records for all critically ill patients older than 18 years of age who were admitted to the surgical ICU, 
medical ICU, trauma/burn ICU, or neurocritical care unit at Michigan Medicine between June 1, 2014 
and June 1, 2017 were reviewed for inclusion in the study. Eligible patients received at least 72 hours of 
continuously infused dexmedetomidine, propofol, or midazolam for ICU sedation. Sedative selection 
was at the discretion of the ICU team. Generally, sedative selection at our institution is guided by the 
recommendations of the Society of Critical Care Medicine guidelines on pain, agitation, and delirium. 
Some variation exists between units and providers, but propofol is the preferred first line agent for most 
patients. Patients were excluded if they had received these medications for other indications, such as 
alcohol withdrawal or status epilepticus, or if a combination of sedatives was simultaneously 
administered. We matched patients in a 3:1 manner between the control group (propofol or midazolam) 
and the study group (dexmedetomidine) based on whether or not they had a history of hypertension.
The primary outcome was incidence of rebound hypertension after cessation of dexmedetomidine 
infusion compared to the control group. Rebound hypertension was defined as receipt of an 
antihypertensive medication in response to hypertension or re-initiation of dexmedetomidine infusion 
due to hypertension within 24 hours of discontinuation. Nursing documentation of blood pressure and 
Richmond Agitation Sedation Scale scores were assessed to ensure that the indication for re-initiation of 
dexmedetomidine was hypertension rather than isolated agitation. Secondary outcomes included the 
effects of cumulative dose and duration of dexmedetomidine on the incidence of rebound hypertension 

















This article is protected by copyright. All rights reserved
Statistical analyses were performed using SPSS version 24. Categorical variables were analyzed with 
Pearson Chi-square test, and continuous variables were analyzed with student’s t-test and Mann-
Whitney U where appropriate. Analyses for primary, secondary outcomes, and subgroup comparisons 
assumed a two-sided significance level of 0.05.
Results
The study population consisted of 216 patients who received dexmedetomidine (n = 54) or propofol or 
midazolam (n = 162) (figure 1). One hundred seventy-six patients received dexmedetomidine and 122 
were excluded, largely due to a duration of therapy less than 72 hours. Baseline characteristics were 
similar between the groups, including severity of illness at admission, age, and gender (table 1). 
There was no difference in the rates of rebound hypertension between the study group and the control 
group (table 2). Rebound hypertension occurred in 16.7% (n= 9) patients in the dexmedetomidine group 
and 17.9% (n=29) patients in the control group (p = 0.837). Patients in the dexmedetomidine group with 
rebound hypertension had a median infusion duration of 77 hours (75-94.5 hours) compared to 114 
hours (101-143 hours) in patients without rebound hypertension (p = 0.01). Among the 9 patients in the 
dexmedetomidine group with rebound hypertension, 77.8% (n=7) had a documented history of 
hypertension, whereas 69% (n=20) of patients in the control group with rebound hypertension had a 
history of hypertension (p = 0.48). Of the 45 patients who received dexmedetomidine who did not have 
rebound hypertension, 33.3% (n=15) had a documented history of hypertension. 
There was no difference in the cumulative dose (expressed as either total dose or weight-based dose 
per day) of dexmedetomidine among patients with rebound hypertension vs patients without rebound 
hypertension (table 2). 
Discussion
A withdrawal syndrome after dexmedetomidine discontinuation has been reported in pediatric patients, 
though hypertension was accompanied by other symptoms of withdrawal including emesis and 
tachycardia.8,9 In one of the cases, withdrawal from opiates and/or benzodiazepines may have 
contributed to the symptoms. 8 Kukoyi et al. reported two cases of possible dexmedetomidine 
withdrawal in adult patients who developed hypertension, tachycardia, and agitation.10 The patients 
received dexmedetomidine for approximately 144 and 168 hours with infusion rates of up to 1.4 
mcg/kg/hr. One patient experienced mydriasis and diaphoresis. 
Ours is the first comparative study to evaluate the risk of rebound hypertension after dexmedetomidine 
discontinuation. Our analysis demonstrated that patients who received continuous infusions of 
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other continuously infused sedatives. Instead, patients with a prior history of hypertension were more 
likely to experience rebound hypertension regardless of the type of sedative used.  Indeed, in the 
dexmedetomidine cohort, 47% of patients with a history of hypertension experienced rebound 
compared to 6.6% of patients without a history of hypertension.  Similarly, 43% of patients in the 
propofol and midazolam group who had a history of hypertension experienced rebound compared to 
10% without a hypertension history. These findings highlight the need for clinicians to appreciate a 
patient’s prior hypertension history in order to carefully titrate sedation or re-institute anti-hypertensive 
therapy.  Lastly, the duration of dexmedetomidine infusion did not influence occurrence of rebound 
hypertension suggesting that drug exposure may not predict the likelihood of this adverse event. The 
lack of difference in cumulative dose between those two subgroups supports that notion. 
Though total drug exposure may not be related to the likelihood of rebound hypertension, it is possible 
that discontinuing the medication too quickly may be harmful. Certainly that is the implication of the 
warning in the package labeling. From a retrospective perspective, it was expectedly difficult to assess 
motivation, intention, or strategy underlying decisions about the method of discontinuing 
dexmedetomidine. 
The interpretation of our data is limited by its retrospective nature. It is possible that documentation of 
preexisting hypertension or reporting of infusion rates or vital signs could be incomplete. Also, we are 
limited to reporting clinical practice as it is, rather than the effects of rigorously controlled sedation 
strategies with pre-defined titration and weaning that one might find in a prospective, randomized 
study. Physician prescribing preferences also may have led to differences in baseline characteristics. 
Nonetheless, our study refines our understanding of dexmedetomidine discontinuation. The risk of post-
discontinuation rebound hypertension is no different with dexmedetomidine than alternate sedatives. 
However, patients with a history of hypertension may be at higher risk. A longer weaning schedule may 
be most appropriate for that subgroup of patients, regardless of which sedative infusion they received. 
While a longer wean may not always be possible depending on the sedative selected, it is an important 
consideration. Alternate choices are worthy of consideration. For example, clonidine could be used in 
patients receiving dexmedetomidine or enteral benzodiazepines for patients receiving propofol or 
midazolam may represent options to provide a longer wean but avoid prolonged duration of mechanical 
ventilation related to sedative infusions.
Finally, it is possible that we did not capture all potential rebound phenomena by limiting the definition 
to 24 hours after stopping sedation therapy. This would be particularly relevant with midazolam as it 
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patients and 58 midazolam patients in the control group. There was no significant difference between 
the propofol or midazolam patients with respect to incidence of rebound hypertension in patients who 
had a history of hypertension. Although it is possible that there were too few patients in the midazolam 
group to detect a true difference.
Conclusions 
When compared to either propofol or midazolam, dexmedetomidine did not increase the incidence of 
rebound hypertension upon discontinuation. Hypertension history appears to be associated with an 
increased risk of rebound hypertension, regardless of which sedative medication is selected. In patients 
with a history of hypertension, a longer titration of dexmedetomidine may be most appropriate. 
However, in other patients, less time on sedation may allow for better outcomes as well as lower 
medication costs. 
References
1. Stewart M, Burris JF. Rebound hypertension during initiation of transdermal clonidine. Drug 
Intell Clin Pharm 1988; 22:573-574.
2. Backo AL, Clause SL, Triller DM. Clonidine-induced hypertension in a patient with a spinal lesion. 
Ann Pharmacother 2002; 36:1396-1398.
3. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs 
lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS 
randomized controlled trial. JAMA. 2007 Dec 12;298(22):2644-53.
4. Ruokonen E, Parviainen I, Jakob SM, et al. Dexmedetomidine versus propofol/midazolam for 
long-term sedation during mechanical ventilation. Intensive Care Med. 2009 Feb;35(2):282-90.
5. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically 
ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99.
6. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for 

















This article is protected by copyright. All rights reserved
7. Ozaki M, Takeda J, Tanaka K, et al. Safety and efficacy of dexmedetomidine for long-term 
sedation in critically ill patients. J Anesth. 2014;28(1):38-50.
8. Darnell C, Steiner J, Szmuk P, Sheeran P. Withdrawal from multiple sedative agent therapy in an 
infant: is dexmedetomidine the cause or the cure? Pediatr Crit Care Med. 2010 Jan;11(1):e1-3.
9. Weber MD, Thammasitboon S, Rosen DA. Acute discontinuation syndrome from 
dexmedetomidine after protracted use in a pediatric patient. Paediatr Anaesth. 2008 
Jan;18(1):87-8.
10. Kukoyi A, Coker S, Lewis L, Nierenberg D. Two cases of acute dexmedetomidine withdrawal 
syndrome following prolonged infusion in the intensive care unit: Report of cases and review of 
















This article is protected by copyright. All rights reserved
Tables
Table 1. Baseline Characteristics
Baseline Characteristics
Dexmedetomidine Arm (n 
= 54)
Propofol or 
Midazolam Arm (n = 
162)
P-value
Age, median (IQR) years 49 (33.25-66.75) 55.5 (39.5-66) 0.508
Male, n (%) 33 (61.1) 81 (50) 0.269















Length of Stay, median (IQR) days 27.5 (20.25-45.75) 26 (16-41) 0.161
APACHE III Score, median (IQR) 80 (56-88) 67 (49-80) 0.187
IQR – interquartile range; MICU – medical intensive care unit; NCCU – neurocritical care unit; SICU – 
surgical intensive care unit; TBICU – trauma and burn intensive care unit; APACHE – Acute Physiology 






Midazolam Arm (n = 
162)
P-value
Incidence of rebound hypertension, 
n (%)
9 (16.7) 29 (17.9) 0.837
Secondary Endpoints and Subgroup Analyses
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(n = 9) Hypertension (n = 45)
Amount of dexmedetomidine, 
median (IQR) mcg
3354.4 (2785.6-6061.6) 7528.4 (3804.8-10730.8) 0.072
Amount of dexmedetomidine, 
median (IQR) mcg/kg/day
13.21 (11.09-15.76) 14.23 (8.14-23.58) 0.880
Duration of dexmedetomidine, 
median (IQR) hours
77 (75-94.5) 114 (101-143) 0.01
Time from peak infusion rate to 
discontinuation, median (IQR) 
hours
4 (3-10) 17 (8-32) 0.011
Amount of infusion time with 
appropriate awakening trials, 
median (IQR) percentage
33.3 (14.3-33.3) 40 (14.3-50) 0.367
IQR – interquartile range
Figure Legends
Figure 1. Trial Profile
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